Abstract: When there are a plurality of concentration value candidates, an extreme value of the calibration curve is detected, and the number of calibration points respectively contained in a region having a low concentration and a region having a high concentration is calculated using the extreme value as a boundary. If there is a difference between the numbers of calibration points of both regions, a concentration value candidate present in the region having a larger number of calibration points is selected as a quantitation result. When the numbers of calibration points are the same, the sign of the coefficient of the term of the second degree of the calibration curve is assessed, and a concentration value candidate present in a region in which the relationship between peak area values and concentration values is monotonically increasing is selected as a quantitation result.

Abstract: Methods and systems are for determining the concentration of a chemical species in an analyte solution. At least one train of segments are injected into a microfluidic channel having a first end and a second end, each train of segments having segments of analyte solution and segments of sensing solution which are immiscible with the segments of analyte solution. The train of segments is circulated from the first end to the second end of the microfluidic channel such that a reversible chemical exchange is established between the chemical species of each segment of analyte solution and a chemical indicator of the at least one contacting segment of sensing solution. The response of the chemical indicator is measured at the second end of the microfluidic channel and the concentration of the chemical species in the analyte solution is determined based on the response.

Abstract: Color-change compositions for detecting urine and feces volatiles include the following pH indicator dyes: m-Cresol Purple, Basic Fuchsin, Brilliant Blue G, Brilliant Blue R, Cresol Red and Thymol Blue. The compositions may be applied to various substrates. Such substrates may be used in the construction of a personal care absorbent article such as a diaper, training pant or incontinence garment.

Abstract: A sensor array includes a circuit board, a plurality of first sensing units, and at least one second sensing unit. The circuit board has an upper surface and a lower surface that are opposite to each other. The first sensing units are located on the upper surface of the circuit board. The first sensing units include a plurality of first electrodes and a plurality of sensing material layers. The sensing material layers are respectively located on surfaces of the first electrodes, and the sensing material layers are manufactured through applying a non-contact printing method. The second sensing unit is located on the upper surface of the circuit board. The second sensing unit includes a second electrode separated from the first electrodes. The sensing material layers respectively cover the surfaces of the first electrodes, and the second electrode is exposed to an atmospheric environment.

Abstract: Method and system for detecting and/or quantifying recent human presence in an environment using a calculated rate of decay of carbon dioxide concentration levels within that environment. A sensor measures the change in carbon dioxide levels over time to calculate the rate of decay to equilibrium and extrapolate recent human presence. Also provided is a method and system for quantifying recent human activity in an environment using the calculated rate of decay to equilibrium.

Abstract: The invention is a method of assessing at least one petroleum characteristic of a rock sample. Starting from a temperature ranging between 50° C. and 120° C., the temperature of a rock sample is raised to a temperature ranging between 180° C. and 220° C. which is maintained for a predetermined time duration. The temperature of the sample is increased to a temperature ranging between 330° C. and 370° C. which is maintained for a predetermined time duration. The temperature of the sample is then raised to a temperature ranging between 630° C. and 670° C. Three quantities representative of the amount of hydrocarbon compounds released during the temperature change stages are measured and at least one petroleum characteristic of the sample is deduced from these quantities.

Abstract: A method is presented for using the time derivative of distributed temperature sensing data to monitor and analyze cement critical temperature Time derivative of DTS in depth and time scale changes during the cementing process in subsurface wells.

Abstract: Embodiments are described for separating/collecting components from a multi-component fluid such as whole blood. Some embodiments provide for controlling the amount of a component, such as platelets, introduced into a separation chamber to ensure that the density of fluid in the separation chamber does not exceed a particular value. This may provide for collecting purer components. Other embodiments may provide for determining a chamber flow rate based on a concentration of a component in the multi-component fluid, which may then be used to determine a centrifuge speed, to collect purer concentrated components.

Abstract: Disclosed is a method for labeling, detecting and/or isolating Foxp3+ Treg cells from a biological sample containing peripheral blood mononuclear cells (PBMC) or lymphocytes including the following steps of: (i) coupling the surface of PBMC or lymphocytes to a capture moiety which binds to the cell through a cell surface molecule and to interleukin-34 (IL34), (ii) culturing the lymphocytes under conditions wherein IL34 is secreted, released and specifically captured by the capture moiety, (iii) labeling the IL34 expressing lymphocytes with a label moiety, and (iv) optionally detecting and/or isolating the IL34 expressing lymphocytes which are Foxp3+ Treg cells. Also disclosed is an isolated population of Foxp3+ Treg cells obtainable by the method and uses thereof.

Abstract: Methods for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates are disclosed. Alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars are incorporated into cellular glycoconjugates. Chemical probes comprising an azide group and a visual or fluorogenic probe and used to label alkyne-derivatized sugar-tagged glycoconjugates are disclosed. Chemical probes bind covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and are visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA, confocal microscopy, and mass spectrometry.

Abstract: A method for identifying the expression or activity of a nuclear protein in a cell, the method comprising: analyzing multiple images of one or more labeled genetic entities; determining from said analysis, a motile property of said one or more labeled genetic entities; and identifying an expression or activity of a nuclear protein of said cell associated with said motile property.

Abstract: Systems for assaying human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are provided. Aspects of the systems include a traction force microscopy substrate, such as a traction force microscopy hydrogel (TFM-hydrogel), having an adhesion protein domain on a surface thereof; a video imager configured to obtain video data from an hiPSC-CM present on the adhesion protein domain; and a processing module configured to receive the video data and derive a parameter of the hiPSC-CM therefrom. Also provided are methods of using the systems.

Abstract: Application of the present invention enables quantification of fractions of candidate pharmaceutical compounds (a parent compound and its metabolites), one excreted to the basolateral (Basal/Basolateral)-side via transporters and by diffusion, one excreted to the lumen (Apical)-side, and one remained in the cells. This enables determination of the total amount of the administered candidate pharmaceutical compounds and the distribution ratio of the fractions. The kinetics of the administered candidate pharmaceutical compounds can be evaluated, thereby enabling in vitro screening of an enormous number of candidate pharmaceutical compounds for drug candidates exhibiting the efficacy.

Abstract: A synthetic organ includes one or more airways and a first opening in communication with the one or more airways configured to introduce a vapor, aerosol, or other airborne material into the one or more airways; an organ-on-chip microfluidic device having respiratory tract or lung tissue or cells; and one or more mounting positions within the one or more airways configured to accept the organ-on-chip microfluidic device, the mounting position(s) configured to accept the organ-on-chip microfluidic device are at a position relative to the first opening to replicate specific portions of a lung.

Abstract: A capsule suitable for oxygen and temperature sensing contains: i) at least one first sensitizer compound being capable of energy transfer to triplet oxygen, ii) at least one compound being capable of reacting with and inactivating singlet oxygen, iii) at least one second sensitizer compound being capable of absorbing radiation at a second frequency v2 and of emitting light at a fourth frequency v4, iv) at least one emitter compound, wherein the at least one second sensitizer compound is capable of transferring energy to the at least one emitter compound and wherein the at least one emitter compound, after obtaining energy transferred from the at least one second sensitizer compound, is capable of emitting light at a third frequency v3, wherein the following equation is fulfilled: v3>v2, wherein the upper energy limit of the first triplet energy band of the first sensitizer compound is lower than the lower energy limit of the second triplet energy band of the second sensitizer compound and lower than the

Abstract: Certain embodiments of the invention are directed to evaluating and identifying cells by recording and interpreting a time-dependent signal produced by unique cell respiration and permeability attributes of isolated viable cells.

Abstract: A system, method, and article for diagnosing a test set of biological cells. For example, in one embodiment a normal set of cells is characterized using flow cytometry. A centroid and radius are defined for a set of clusters in an n-dimensional space corresponding to a normal maturation for a cell lineage in the normal set of cells. A test set of cells is characterized using flow cytometry and the characterization is compared to the set of clusters.

Abstract: A machine for automatic in vitro detection of analytes, the machine being of the type comprising an optical reader device (30) capable of detecting the optical response of the reaction solution to electromagnetic stimulation using a photoelectric receiver (70) that is carried by a movable carriage (32) of the machine and that moves under automatic control in order to bring the photoelectric receiver into various positions, each corresponding to various respective analysis zones (26?), the machine being characterized in that the photoelectric receiver (70) forms part of a spectrometer (64) capable of delivering a chromatic spectral decomposition of the optical response. The invention also provides methods of automatic in vitro detection and/or quantification of analytes. In one method, a chromatic spectral decomposition of the optical response is acquired and two distinct optical agents are detected separately by means of said spectral decomposition.

Abstract: A method for image analysis of medical test results, comprising receiving information from a mobile device application regarding a test performed using a testing device, wherein the testing device includes a plurality of immunoassay test strips and at least one test function indicator on a surface thereof, wherein the mobile device application is configured to recognize the at least one test function indicator to trigger performance of one or more of the plurality of medical test functions, receiving at the server an image of the testing device from the mobile device application, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing the single value to a control value, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

Abstract: The invention pertains to an isolated VH single domain antibody comprising a C-terminal modification, where the C-terminal modification comprises a deletion of at least one amino acid residue that eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.

Abstract: This invention allows ultra-low levels of virtually any biological analyte to be detected and quantified rapidly, simply and inexpensively with an electrochemical biosensor using a novel electrochemically detectable tag that replaces optical labels. The tag binds to an analyte directly, or indirectly using one or more ligands and particles, and consists of a quadruplex electrochemically detectable oligonucleotide rich in guanine, or a single-stranded electrochemically detectable oligonucleotide rich in guanine that self-assembles into a quadruplex electrochemically detectable oligonucleotide when exposed to cations that enable quadruplex self-assembly. Quadruplex electrochemically detectable oligonucleotide tags are exposed, adsorbed or hybridized at the surface of a biosensor working electrode. An electrochemical technique facilitates the quadruplex tags to produce 8-oxoguanine oxidation signals proportional to the analyte level in the samples.

Abstract: The invention provides peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens. The peptide compositions and mixtures comprise polypeptide sequences based on an immunogenic fragment of the Ehrlichia Outer Membrane Protein 1 (OMP-1) protein. The invention also provides devices, methods, and kits comprising such peptide compositions and mixtures useful for the detection of antibodies that bind to Ehrlichia antigens and the diagnosis of monocytic and/or granulocytic ehrlichiosis.

Abstract: A thrombin-antithrombin complex (TAT) assay reagent is described in which the thrombin-antithrombin complex (TAT) assay reagent includes an antibody bound to a latex particle which binds to the antithrombin part of the complex, and an antibody bound to a latex particle which binds to the thrombin (T) part of the complex. The antibody binding to the antithrombin part of the complex has a reactivity to TAT that is 100 or more times higher than the reactivity to free antithrombin and the assay reagent is preferably designed to achieve a pH of 5.8 to 6.6 during the assay.

Abstract: A method for determining a radius of elements suspended in a medium includes binding the elements to nanoparticles to form bound element-nanoparticle aggregates, superposing first and second Doppler-shifted optical waves having a variable frequency shift between them in the medium such that there is a gain in energy of the first optical wave with respect to the second optical wave, varying the frequency shift and measuring the gain while varying the frequency shift to determine the value of the frequency shift at which there is a peak in the gain, determining the radius of the bound element-nanoparticle aggregates based on the value of the frequency shift at which there is a peak in the gain, and determining the radius of the elements based on the radius of the bound element-nanoparticle aggregates.

Abstract: Disclosed herein are formulations, substrates, and arrays. In certain embodiments, methods of attaching a biomolecule to an array using a photoactivated conjugation compound are disclosed. Methods of generating site-specific attachment of biomolecules to an array are also disclosed. Arrays generated by these methods and methods of using these arrays are also disclosed.

Abstract: Provided is a biological sensing system, including a nanowire field-effect transistor and a sensing chip. A gate terminal of the nanowire FET surrounds a gate of a silicon nanowire or a gate of a silicon nanobelt, diameter of the silicon nanowire is less than 20 nm. A sensing electrode of the sensing chip is coupled to the gate terminal of the nanowire FET. An area ratio of an electrode area of the sensing electrode to a total sensing chip area, a thickness ratio of an oxide thickness of sensing electrode to a bulk oxide dielectric film thickness of the sensing chip and a capacitance ratio of an electrode capacitor of the sensing electrode to a gate capacitor of the silicon nanowire or a gate capacitor of the silicon nanobelt are optimized by means of an equivalent circuit so that potential coupling efficiency between sensing electrode and gate is optimized.

Abstract: Apparatus for determining the quantity of a target analyte present in a sample, the apparatus comprising: a first plate comprising a plurality of recesses arranged to form a plurality of rows extending parallel to one another, and a plurality of channels extending perpendicularly to the plurality of rows of the first plate; and a second plate comprising a plurality of recesses arranged to form a plurality of rows extending parallel to one another, and a plurality of channels extending perpendicularly to the plurality of rows of the second plate; wherein the first plate and the second plate are assembled together so that the first plate is positioned against the second plate and the recesses of the first plate communicate with the recesses of the second plate so as to form a plurality of sample rows, a plurality of control rows, and an ink row disposed between the plurality of sample rows and the plurality of control rows.

Abstract: Embodiments of the invention relate generally to devices and methods for pumping and controlling the flow of a fluid. More particularly, embodiments of the invention relate to capacitive pumping and flow control devices and methods. In one embodiment, the invention provides a pump system having an inlet valve, an outlet valve, and a chamber between and in communication with each of the inlet valve and the outlet valve, the chamber having at least one elastic surface, wherein the chamber will dilate in response to a fluid exerting a pressure on the elastic surface, contain a quantity of the fluid when so dilated, and discharge the quantity of the fluid through the opened outlet valve.

Abstract: In some aspects, the present disclosure relates to a lateral flow test device, a kit or an instrument comprising the test device, and a method of using the test device, kit, or instrument for quantitatively detecting an analyte in a saliva sample, e.g., a saliva sample from a subject, for example, for assessing hormone(s), ovulation, pregnancy, and/or fertility for a user, e.g., hormonal, ovulation, pregnancy, fertility status, time window, trend, or therapy monitoring or guidance for the user.

Abstract: Disclosed herein are improved methods of assessing ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) status in a subject (such as for example, as a measure of traumatic brain injury or for other clinical reasons). Also disclosed herein are methods of assessing a subject's glial fibrillary acid protein (GFAP) and UCH-L1 status in subject (such as, for example as a measure of traumatic brain injury or for other clinical reasons).

Abstract: This invention relates to assays which screen for compounds that modulate taste elicited by the T1R2/T1R3 sweet taste receptor which include a novel counter screen to eliminate false positives. In addition, the invention contemplates assays which screen for compounds that modulate taste elicited by the T1R1/T1R3 umami taste receptor which include a novel counter screen to eliminate false positives. Preferably the assays are conducted in high throughput format thereby enabling the screening of many hundreds of different compounds whereby the counter screen significantly improves assay efficiency. Further, the invention relates to the use of the compounds identified in the subject screening assays to modulate T1R associated taste perception.

Abstract: Methods are provided to detect and treat a fungal infection. The method may include the steps of obtaining a sample from a subject suspected of having a fungal infection, detecting an Uncharacterized Fungal Protein (CIMG_09001/CPSG_01366) in the sample, and determining the presence on the fungal infection if the Uncharacterized Fungal Protein is detected.

Abstract: A method for collection and dissemination of biologic data, comprising collecting at least one biologic sample by a testing device including thereon an alignment target and including a plurality of immunoassay test strips, wherein the at least one biologic sample contacts a sample pad on at least one of the plurality of immunoassay test strips, assigning correlative values as test results, wherein each test performed on the biologic sample is assigned a different correlative value, receiving the test results at a server disposed on a network, wherein the server has configured thereon a database, assigning a unique identification to the biologic sample, storing the unique identification in the database, storing the test results in the database in association with the unique identification of the biologic sample, and providing access to the database to healthcare organizations for analysis of the test results.

Abstract: An immediate health assessment response system, comprising a testing device having thereon an alignment target and having a plurality of immunoassay test strips, the plurality of immunoassay test strips each including a sample pad capable of receiving a biologic sample, and a server configured to receive information from a mobile device regarding test results from a test performed using the testing device, receive an image from a mobile device, process the image to determine results based on pixel count and line intensity of the test line of each of the plurality of immunoassay test strips, compare the results of processing the image to a control for each test line of each of the plurality of immunoassay test strips, and provide a risk indicator, wherein the risk indicator alerts a user to seek medical attention immediately.

Abstract: This invention concerns patentable devices configured to capture cancer stem cells and cell clusters. After capturing such cells and/or clusters, the cancerous cells are subjected to whole genome sequencing. The resulting genomic sequence information is then compared to that for “normal” or non-diseased tissue (obtained, for example, from either the same patient, or a population sample, etc.) in order to identify the specific genetic mutation(s) present in the CSCs. Further analysis then correlates the genetic mutations with cell growth signaling pathways typically found with tumor metastases. Armed with this information, an oncologist can then develop a specifically targeted therapy that utilizes approved drugs or drug candidates undergoing clinical testing to address the identified driver mutations and thus effect a “targeted” therapy tailored to the particular patient's disease.

Abstract: A method for detecting aggressive tumor behavior and/or increased risk for tumor metastasis generally includes analyzing a tumor sample from the subject for expression of transcripts from coding regions of the cell cycle gene cluster, the immune-1 gene cluster, or the immune-2 gene cluster; computing a sum of log2-transformed mean-centered expression values, thereby generating a Gene Cluster Expression Summary Score (GCESS) for the sample; and detecting a tumor with aggressive behavior and/or increased risk for tumor metastasis. An aggressive tumor and/or increased risk for tumor metastasis may be indicated where the cell cycle gene cluster is analyzed and the sample GCESS is greater than 0, or the immune-1 gene cluster or the immune-2 gene cluster is analyzed and the sample GCESS is less than 0.

Abstract: Provided are methods, compositions, kits, and systems for determining the risk that a subject who does not have dysplasia will develop dysplasia and/or esophageal cancer.

Abstract: Methods for measuring a panel of biomarkers in a subject suspected of having breast cancer are provided. The methods include obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least 5 biomarkers selected from the group comprising LPC(18:3), LPC(20:2), LPC(20:1), LPC(20:0), PC(32:1), PC(34:4), PC(38:3), PC(40:5), PC(40:3), PC(44:11), ePC(32:2), ePC(38:3), C19:1 CE, C19:0 CE, and C20:0 CE, wherein the measurement comprises measuring a level of each of the at least 5 biomarkers.

Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.

Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.

Abstract: Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.

Abstract: Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.

Abstract: The present invention relates to a core/shell nanoplatelet and its use as a fluorophore or a fluorescent agent.

Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease.

Abstract: This document relates to methods for quantifying antibody therapeutics using mass spectrometry techniques.

Abstract: Disclosed herein are methods and systems for detecting CD3 and CD16 in the same sample of a colorectal, head & neck, or lung tumor using immunohistochemical methods using primary antibodies from the same host species and secondary antibodies immunoreactive with antibodies of the host species of the primary antibodies. Methods to denature and block the first primary antibody contacted with the sample are provided.

Abstract: The present invention relates to a method of diagnosing a renal disorder. The method includes the steps of: (1) obtaining a biological sample from a subject; and (2) determining, in the biological sample, a level of one or more proteins whose abundance in urine change due to the renal disorder, wherein an increase or decrease in the level of one or more of the proteins compared to a control level is indicative of a renal disorder.

Abstract: Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).

Abstract: The present invention provides a cocaine aptamer represented by the following chemical formula (Cl), R-DNA-L-Fc??(Cl) where R is selected from the group consisting of a hydrocarbon group and the derivative thereof; DNA consists of a gene sequence capable of binding to cocaine; L is a linker represented by ((CH2)2—O)n1—PO4—(CH2)n2-L1; L1 is absent or an optional linker; n1 represents a natural number; n2 represents a natural number; and Fc represents a ferrocene group. The cocaine aptamer is capable of detecting cocaine with high sensitivity.

Abstract: In the prior art, variability arises in a rotational stopping position depending on the location in which reading of a bar code begins, and it is possible to conceive of situations in which there is inadequate orientational alignment of the bar code relative to the slit after rack transfer, as a result of which it is not possible for the bar code to be read by an analysis system. Accordingly, a first rotation is performed, in which a specimen container having a non-printed region and a printed region on a side surface thereof is rotated intermittently, each time through a certain angle. Additionally, information printed on the printed region on the side surface of the specimen container is read while the first rotation is being performed, and the location of the non-printed region of the specimen container is identified on the basis of the success or failure of said reading. Next, a second rotation is performed, in which the specimen container is rotated continuously.